Eliminating HCV co-infection in HIV: A Positive Health Clinic (PHC) Venture

Abstract Background HCV/HIV co-infected patients have a higher risk of liver disease progression and mortality despite highly effective ART. Near 100% cure rate for HCV infection can be achieved by current direct-acting agents (DAA) against HCV. Therefore, treatment for all patients with HCV/HIV has been recommended by IDSA/AASLD. Setting PHC is a Ryan White Care Act funded HIV outpatient clinic providing care for approximately 900 patients in Pittsburgh, PA. Methods At our clinic, a quality improvement project incorporating treatment algorithms targeting HCV/HIV was established for providers to guide HCV therapy. Results From January 1, 2014 to April 30, 2017, a total of 71 (12 F 59 M; 35 AA/1 H/35 W; Risk: 38 IVDU/31 MSM) HCV/HIV co-infections were identified (GT1: 57; GT3: 6; GT4: 1) with median age of 52 years (range: 21–73). Among them, 21 had fibrosure scores ≥ 3 and 22